# A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia

Study · id `cardio:ct-nct07100418` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07100418](<https://clinicaltrials.gov/study/NCT07100418>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07100418

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 224 participants.

## Technical summary

Registry record NCT07100418. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-12 (actual); primary completion 2026-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 224 participants (enrolled count; ClinicalTrials.gov record NCT07100418, source copy `cardio:ctgov-nct07100418-2026-06-03`, retrieved 2026-10-31)
- Started: 2025-08-12 (actual) (ClinicalTrials.gov record NCT07100418, source copy `cardio:ctgov-nct07100418-2026-06-03`, retrieved 2026-10-31)
- Primary completion: 2026-09 (anticipated) (ClinicalTrials.gov record NCT07100418, source copy `cardio:ctgov-nct07100418-2026-06-03`, retrieved 2026-10-31)
- Completion: 2027-01 (anticipated) (ClinicalTrials.gov record NCT07100418, source copy `cardio:ctgov-nct07100418-2026-06-03`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07100418, source copy `cardio:ctgov-nct07100418-2026-06-03`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07100418-2026-06-03`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia
- Condition: Hyperlipidemia
- Intervention (Drug): HRS-7249 Injection
- Intervention (Drug): Sodium Chloride Injection
- Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. (`cardio:org-fujian-shengdi-pharmaceutical-co-ltd`)

## Provenance

Content hash: 9a3bcb2eaa6c493c0f3c3c43cdbbc65620e9ad9e3668bcb8642d54e3a9b8223f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
